https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2024-0137
Announcing a new article publication for
BIO Integration journal. Diabetes mellitus (DM) is a widespread metabolic disorder with profound effects on vital organs. Often referred to as a “systemic” or “multi-organ” disorder due to the impact on key organs, such as the kidneys, pancreas, eyes, and heart, DM is characterized by elevated blood glucose levels due to insufficient insulin production. DM consists of three subtypes (type 1 DM, type 2 DM, and gestational DM). Approximately 537 million adults are living with DM, a number predicted to increase to 643 million by 2030, according to the International Diabetes Federation (IDF) data. With the rising prevalence of DM, the Pan American Health Organization and World Health Organization estimate an age-standardized mortality rate of 20.9 deaths per 100,000 people. Therefore, it is important to study the prevention and cure of DM and determine the underlying mechanism and regulation. Numerous receptors and pathways help to regulate DM. This article delves into the intricate regulatory mechanisms underlying DM involving receptors and pathways, such as K
ATP (sulfonylurea), 5′AMP-activated protein kinase enzyme (biguanides), PPAR gamma, alpha-glucosidase, Glucose transporters (GLUT4), dipeptide peptidase-4 (DPP-4), and sodium-glucose co-transporters type 2 (SGLT2). Recent advances from 2020–2024 in synthesizing compounds targeting specific receptors for diabetes management are highlighted. In so doing, insights into newly synthesized compounds, marketed drugs, phytoconstituents, and drugs currently in clinical trials are provided. The role of each receptor in maintaining glucose homeostasis is reviewed in detail and various compounds with potential as effective antidiabetic agents are evaluated. This comprehensive review presents the pharmacologic mechanisms underlying these receptors and an in-depth analysis of promising new drug candidates.
# # # # # #
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience,
BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.
BIOI is now open for submissions; articles can be submitted online at:
https://mc04.manuscriptcentral.com/bioi
Please visit
www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
Please visit
www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
BIOI is available on the
IngentaConnect platform (
https://www.ingentaconnect.com/content/cscript/bioi) and at the
BIO Integration website (
www.bio-integration.org).
Submissions may be made using
ScholarOne (
https://mc04.manuscriptcentral.com/bioi).
There are no author submission or article processing fees.
Follow
BIOI on Twitter
@JournalBio;
Facebook (
https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and
LinkedIn (
https://www.linkedin.com/company/bio-integration-journal/).
ISSN 2712-0074
eISSN 2712-0082
Pallavi Pandey, Vikash Jakhmola and Supriyo Saha et al. Recent Developments in Diabetes Management: Exploring Receptors, Pathways, and Compounds.
BIOI. 2025. Vol. 6(1). DOI: 10.15212/bioi-2024-0137
# # # # # #